search.noResults

search.searching

note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
WWW.IDAIRELAN.COM


in 2004 by Professors Timothy O’Brien and Frank Barry. They shared a vision for the establishment of a research and technology centre that would be a key contributor to the development of innovative therapies to treat major chronic and debilitating conditions, utilising cell and gene therapies. To achieve these objectives, REMEDI has put in place strongly translational research programmes to accelerate the delivery of these new treatments to patients, and to provide strategies for successful commercialisation. This


T is a very exciting time in the


regenerative medicine industry as progress continues to be made in terms of the development important


of novel therapies, with clinical proof emerging and


he Regenerative Medicine Institute (REMEDI) in Galway was established


achieve these objectives, strong and


strategically important partnerships were forged with many companies. These collaborations have included Medtronic, Boston Scientific, Smith & Nephew, DePuy Synthes, Creganna Medical, AbbVie, Ovagen, Orbsen Therapeutics, Human Med, Crospon, Aerogen and many others.


STEM CELL RESEARCH The


objective programme in stem cell biology


of REMEDI’s research is


to


enhance understanding of the biological regulation of adult stem cells, to validate selected cell-based therapies in pivotal preclinical studies, to develop new testing systems for release of cellular products in a regulated environment, and to establish GMP-compliant manufacturing systems.


total global financing in 2016 has been estimated at $5.22 billion.”


advanced manufacturing strategies being developed. It


is estimated that there are


about 800 regenerative medicine companies worldwide, with some 400 of these in North America and 200 in Europe. Total global financing in 2016 has been estimated at $5.22 billion, reflecting an exceptional level of interest in these new technologies and a sharp focus on their clinical and commercial potential. Another exciting development in 2016 has been the first approval of a CAR T-cell therapy in the US, paving the way for new cancer treatments that


were


inconceivable a few years ago. New approaches to gene


editing using tools


known as CRISPR-Cas have also gained traction and have been tested in humans for the first time in 2016. This technology has the potential to transform cancer therapy and provide new ways to treat rare inherited diseases. Similarly, the field of cellular therapy for wound repair and inflammatory diseases has progressed at a fast pace. Critical support


for REMEDI was


provided at the outset by Science Foundation Ireland and this lead to rapid growth in the areas of fundamental stem cell science, preclinical


manufacturing


testing, advanced therapeutic and


clinical trials.


REMEDI’s mission was straightforward: to develop new approaches to patient care that would focus on tissue repair and regeneration using minimally invasive approaches. To


33 ISSUE 13


IMMUNOLOGY The REMEDI Immunology Programme, led by Professors Matthew Griffin, Rhodri Ceredig and Thomas Ritter, works towards


These topics are addressed in a series of projects that have as their objective the greater understanding of how stem cells behave in their natural environment and how the cells interact with the injured host in the context of tissue repair. In addition to the therapeutic use of stem cells, REMEDI has also developed a programme to explore the opportunities associated with induced pluripotent stem cells (iPSC). The ability to reprogramme somatic cells, for example cells taken from a skin biopsy, provides exciting opportunities in understanding disease mechanisms and provides a powerful strategy for drug screening and for understanding new therapeutic interventions. The areas of emphasis in the iPSC research programmes include research


into neurodevelopmental


neurodegenerative autism,


schizophrenia and and


conditions, such as Parkinson’s


disease under the leadership of Professor Sanbing Shen, and bone and joint diseases, such as osteoarthritis and osteopetrosis, led by Frank Barry. At


this time there is a


substantial repository of patient iPSC lines which provides an important resource in understanding these conditions.


“There are about 800 regenerative medicine companies worldwide…


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60